Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment

A Narrative Review of Literature for Clinical Practice

Emily Figueiredo Neves Yuki, MD; Clovis A. Silva, MD, PhD; Nadia E. Aikawa, MD, PhD; Ricardo Romiti, MD, PhD; Carlos Otto Heise, MD, PhD; Eloisa Bonfa, MD, PhD; Sandra Gofinet Pasoto, MD, PhD


J Clin Rheumatol. 2021;27(6):248-259. 

In This Article


Lenalidomide is an analog of thalidomide by subtraction of an oxy group from the phthaloyl ring, which is replaced by an amino group.[95] This new synthetic drug was approved by the Food and Drug Administration for treatment of multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.[96]